2025-12-19 - Analysis Report
Here's a comprehensive analysis of Transmedics Group Inc. (TMDX) based on the provided data:

**0) Simple Numbers and Analysis:**

*   **TMDX Overview:** Transmedics Group Inc. is a medical technology company pioneering a novel approach to organ transplantation.
*   **Cumulative Return (TMDX):** 197.98%
*   **Cumulative Return (S&P 500/VOO):** 74.33%
*   **Divergence (TMDX vs. S&P 500):** 132.7 (Relative Divergence: 64.4)
*   **Close Price:** $121.07
*   **5-day SMA:** $123.60
*   **20-day SMA:** $134.06
*   **60-day SMA:** $124.65
*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 6.78
*   **PPO:** -1.82
*   **Expected Return:** 49.8%
*   **Analyst Consensus:** Buy, Target Price: $144.73

**1) Return Rate Comparison (TMDX vs. S&P 500):**

*   TMDX has significantly outperformed the S&P 500 (VOO) over the tracked period.  The cumulative return of TMDX is 197.98% compared to the S&P 500's 74.33%.
*   **Divergence:** The current divergence is 132.7, with a relative divergence of 64.4. This means that the current difference in cumulative returns is positioned at the 64.4th percentile of past divergences, indicating TMDX is still performing strongly relative to its historical performance against the S&P 500.
*   **Alpha/Beta Analysis:** The provided table indicates significant fluctuations in TMDX's performance. While CAGR varied greatly across periods, the Alpha consistently shows strong outperformance relative to the market. Beta remains consistently low, close to zero, indicating it moves less dramatically than the overall market.

**Key Takeaways from Alpha/Beta Analysis:**

*   **High Alpha:** TMDX demonstrated robust outperformance, as indicated by the consistently high Alpha values.
*   **Low Beta:** TMDX's low Beta value suggests it is less sensitive to market movements.
*   **High MDD:** High MDD's means the stock price is quite risky.

**2) Recent Stock Price Fluctuations:**

*   The current price is $121.07, showing a slight decrease from the previous close of $121.93 (-0.71%).
*   The 5-day SMA ($123.60) is slightly below the 20-day SMA ($134.06) and the 60-day SMA ($124.65), indicating a possible short-term downward trend after a period of growth, as the price has fallen to a point below both 5-day and 60-day SMA's.
*   The price had been consistently declining, and the current price is below the price on the 5-day SMA.

**3) Indicator Analysis:**

*   **Market Risk Indicator (MRI) of 0.7** suggests a medium investment recommendation, meaning it has good potential with reasonable risks.
*   **RSI of 6.78** signals that the stock is extremely oversold, potentially indicating a buying opportunity if you believe the stock will rebound.
*   **PPO of -1.82** also confirms the short-term downward momentum, suggesting the stock is in a downtrend.
*   **Hybrid Signal:** Recommends putting 100% of available cash into TMDX (7 shares), highlighting a very safe rating (MRI: 0.90). It also suggests a monthly investment of 1.2% of total investment ($1,000). This is a strongly bullish signal.
*   **Recent Divergence Change:** The recent (20 days) relative divergence change of -7.1 indicates a short-term downward trend.
*   **Expected Return of 49.8%** suggests a potentially high long-term return compared to the S&P 500, making it an attractive investment.

**4) Recent News & Significant Events:**

*   **Positive Analyst Sentiment:** Canaccord Genuity Group raised their price target for TMDX (MarketBeat, GuruFocus), indicating positive expectations for the stock's future performance.
*   **Mixed Outlook:** Zacks Investment Research suggests TMDX and other "skyrocketing MedTech Stocks" might lose steam in 2026, suggesting potential risks in the medium term.
*   **Earnings Beat, but Falls:** Yahoo Finance reported that TMDX stock fell despite Q3 earnings beating estimates, indicating that market sentiment may not always align with financial performance.
*   **Top Stock Pick:** The Motley Fool mentioned TMDX as one of the top stocks to buy in December, reinforcing the overall positive outlook.

**4-2) Analyst Opinions:**

*   **Consensus:** The analyst consensus is "Buy," with a mean rating of 1.67.
*   **Target Price:** The average target price is $144.73, implying a potential upside from the current price.
*   **Recent Rating Changes:** No specific rating changes provided in the context.

**5) Comprehensive Analysis:**

TMDX presents a compelling but nuanced investment opportunity.

*   **Strengths:**  The company has demonstrated strong historical outperformance compared to the S&P 500, as reflected in its high cumulative return and Alpha. Analyst consensus is "Buy," with a target price above the current trading level. Positive news headlines include increased price targets and mentions as a top stock pick. The MRI is medium investment, and the expected return of 49.8% is very high.

*   **Weaknesses/Risks:** Recent news suggests the possibility of TMDX "losing steam" in 2026. The high MDD indicates significant volatility. Short-term technical indicators (RSI, PPO, recent divergence change) indicate a potential downward trend, and earnings beat didn't prevent the price drop, pointing at the market not responding to fundamental data.

*   **Overall:**  While TMDX has demonstrated strong growth and has a positive long-term outlook, the recent price action and analyst warnings suggest potential short-term volatility and the possibility of future deceleration. A strategy based on the hybrid signal is recommended, suggesting accumulating on dips if you are a believer in the company. Pay close attention to upcoming earnings reports, analyst updates, and industry news.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.